Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1701-1720 of 1,743 trials

Cholangiocarcinoma: Ivosidenib Maintenance Therapy

We are studying whether the drug ivosidenib can help patients with mIDH1 cholangiocarcinoma after standard chemotherapy. The trial will also look at its safety and effects on quality of life.

Cholangiocarcinoma Treatment>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

TAILORED-PROM: Personalized Treatment for Preterm Premature Rupture of Membranes

We are studying if a customized antibiotic and steroid therapy can help prolong pregnancy and improve outcomes for mothers and newborns. This approach may reduce unnecessary antibiotic use compared to standard treatments.

Preterm Premature Rupture of Membranes>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInfectious Diseases

Head and Neck Cancer: New Treatment Approach with Pembrolizumab

We are studying a new sequence of treatments for patients with recurrent head and neck cancer to see if it improves survival compared to standard therapies. We will also evaluate how well patients tolerate the treatments and their quality of life.

Recurrent Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: RAXO Trial

We are studying how metastatic colorectal cancer behaves and the effectiveness of different treatments in patients. This research aims to improve surgical options and overall patient outcomes.

Advanced Colorectal Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Breast Cancer: Typology-based Coaching with Ribociclib

We are studying whether personalized coaching and education can help patients with HR+ HER2- early breast cancer stay on their ribociclib treatment. This may improve their treatment experience and overall health outcomes.

Hormone Receptor Positive Breast CancerBreast Cancer>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Cemiplimab for Advanced Adrenocortical Cancer

We are studying whether cemiplimab can help patients with advanced adrenocortical cancer maintain their health after initial treatment. This trial focuses on those who have not experienced disease progression.

Adrenocortical Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Obstructive Pulmonary Disease: Verekitug Study

We are investigating whether Verekitug can help people with moderate-to-severe COPD manage their symptoms and improve lung function. The study will also assess the safety and overall impact on quality of life.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Glioblastoma: Intraoperative Photodynamic Therapy with Pentalafen®

We are studying a new light-based treatment for adults with grade IV glioblastoma during surgery. The goal is to evaluate its safety and how well it works in reducing tumor response.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Hidradenitis Suppurativa: Sonelokimab Study

We are studying the long-term safety and effectiveness of sonelokimab for people with moderate to severe hidradenitis suppurativa. This research aims to improve symptoms and quality of life for participants.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

HIV-1 Prevention: MK-8527 Oral Medication

We are studying a new once-monthly pill, MK-8527, to see if it can effectively prevent HIV-1 infection compared to a daily treatment. The trial will also assess how safe and tolerable this new medication is for participants.

HIV-1>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

HIV Treatment: New Antibody Study

We are investigating whether adding a new antibody to current HIV medications helps reduce the viral reservoir in adults living with HIV. This study aims to improve treatment outcomes for those affected.

HIV Infection>2 yearsSafety phase (I)Infectious DiseasesInternal Medicine

Ulcerative Colitis: RO7837195 Treatment Study

We are testing a new medication, RO7837195, for people with moderately to severely active ulcerative colitis. The study aims to see if it can help induce remission and how safe it is compared to a placebo.

Ulcerative Colitis>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Cemiplimab and Imiquimod for High-Risk Basal Cell Carcinoma

We are studying a combination of cemiplimab, imiquimod, and laser therapy for patients with high-risk cutaneous basal cell carcinoma. The goal is to evaluate safety and how well this treatment works before surgery.

Skin Cancer (Basal Cell Carcinoma)>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyOncology

Fluid Management in Critically Ill Adults: CRUSADERS Trial

We are studying whether reducing sodium and chloride in fluids helps critically ill adults have better health outcomes. This includes looking at effects on organ support needs and overall survival.

Healthy Participants>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrology

Learning Dynamics: Atomoxetine Study

We are investigating how a low dose of atomoxetine affects learning and emotional states in healthy adults. This study aims to understand its impact on learning tasks and emotional well-being.

Healthy Participants>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

Congenital Pseudarthrosis of the Tibia: NVD003 Treatment Study

We are evaluating how effective and safe NVD003 is for children undergoing surgery for congenital pseudarthrosis of the tibia. The study will also look at its impact on bone healing and quality of life.

Congenital Pseudarthrosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Parkinson's Disease: Lecigon® Therapy

We are studying a new treatment combining levodopa and entacapone for people with Parkinson's disease. The goal is to see if it helps reduce certain symptoms and improve overall well-being compared to standard treatments.

Parkinson's Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry